More M&A Deals Could Boost Biotech ETFs

By
Devon Layne
December 12, 2012
Share:

 

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF DAILY DATA

The S&P 500 funds 'SPY' and 'IVV' led inflows on Thursday, Feb. 26, as total U.S.-listed ETF assets dipped to $2.094 trillion

'SPY,' 'MDY, 'XLF' and 'XLY' paced SSgA's issuer-leading inflows on Thursday, Feb. 26, as total U.S.-listed ETF assets fell to $2.094 trillion.

ETF.COM ANALYST BLOGS

By Elisabeth Kashner

Virtu’s mind-bending way to play oil market volatility is a fascinating glimpse into the world of ultra-sophisticated investors.

By Dave Nadig

A reader asks: What happens to ETFs when the market goes nuts?

By Dennis Hudachek

In the growing world of currency-hedged ETFs, Germany strategies are getting short shrift.

By Elisabeth Kashner

A look at ETF.com's powerful revamping of its classification of U.S. total market ETFs.